ISSAR Pharma

Patents

We take pride in being India’s 1st and only
Pharmaceutical Company to exclusively work for
 design and development of NCEs.

Patents

  • Composition for treatment of burns
    and wounds
  • Angiogenic Active Lytic Peptides
  • Peptides for burns, diabetic wounds
    and scar reduction
  • Peptide for treating Inflammatory
    Bowel Diseases (IBD)
  • Peptides with anti-inflammatory and
    anti-angiogenic properties for Psoriasis

1. Issar Pharmaceuticals secures Patent in India & USA “Composition for treatment of burns and wounds”

Patent Update

Issar Pharmaceuticals secures one Patent in United States corresponding to the New Chemical Entity “Composition for treatment of burns and wounds” and patent is valid through 2027. A composition is provided to heal burns, Wounds and other skin traumas of mammals. The composition is useful to treat sepsis and to improve skin formation as Well. The composition comprises an antimicrobial peptide having 23 amino acid sequence with 18 Claims.

2. Issar Pharmaceuticals secures Patent in USA “ANGIOGENIC ACTIVE LYTIC PEPTIDES”

Patent Update

Issar Pharmaceuticals secures one Patent in United States corresponding to the New Chemical Entity “ANGIOGENIC ACTIVE LYTIC PEPTIDES” and patent is valid through 2026. This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of Such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity with 4 Claims.

3. Issar Pharmaceuticals secures Product Patent in USA “composition for the treatment of burns, diabetic wounds , other types of wounds and subsequently greatly reduced scarring”

Patent Update

Issar Pharmaceuticals secures one Patent in United States corresponding to the New Chemical Entity “composition for the treatment of burns, diabetic wounds , other types of wounds and subsequently greatly reduced scarring” and patent is valid through 2037. Antimicrobial peptides represent a relatively new discovery in the immune system path way. Recent designs of synthetically engineered antimicrobial peptides have demonstrated increased potency and efficacy / tolerability, enhanced specificity, and reduced toxicity in comparison. One such peptide, XYLENTRA, has shown / demonstrated significant promise from significant in vitro studies against a large number of pathogens. Additionally, extensive animal studies have shown that the XYLENTRA is an antimicrobial peptide against a large number of pathogens. The XYLEN TRA is also solute resistant. The test compound Xylentra® has shown / demonstrated significant antibacterial activity on test organisms Staphylococcus aureus MTCC 96 and Pseudomonas aeroginosa MTCC 741. A substantial decrease in the microbial population level was observed in animals treated with peptide using the protocol described in detail in the application with 4 Claims

4. Issar Pharmaceuticals secures Patent in India, USA, Australia, EU& South Africa“ Peptide for Treating Inflammatory Diseases”

Patent Update

Issar Pharmaceuticals secures one Patent in United States corresponding to the New Chemical Entity “Peptide for Treating Inflammatory Diseases” and patent is valid through 2036. The invention provides a peptide having anti-inflammatory activity. The invention also provides the method of preparation of the peptide and compositions, and kits comprising the peptide. The invention further provides the method of treating inflammatory diseases employing the peptide of the present invention.

5. Issar Pharmaceuticals secures Patent in India “Anti inflammatory and Anti angiogenic peptides and their uses”

Patent Update

Issar Pharmaceuticals secures one Patent in United States corresponding to the New Chemical Entity “Anti inflammatory and Anti angiogenic peptides and their uses” and patent is valid through 2030. The invention provides a method to treat angiogenesis and inflammatory related diseases, by treating a patient with at least one peptide sequence possessing physico-chemical relatedness peptide sequences with 8 claims.

We have acquired over 7 patents and  commercialized 2 peptide drug molecules . ISSAR takes pride in being India’s 1st and only Pharmaceutical Company to work exclusively in design and development of NCEs. Also, we pioneered in conducting the first clinical trials in India and Phase – I & II Trials for our first ever peptide drug – Melgain.

  • 20+ years of focus on R&D and innovation

  • We addressed some of the greatest challenges in developing peptide-based drugs, related to:

  • Formulation

  • Stability, bioavailability and immunogenicity

  • State-of-the-art 62,000 sqft FDA-compliant manufacturing facility to synthesize peptides

Development Pipeline

A Motivation towards Peptide Drug Discovery to improve patients’ lives

ggggggggggg

Novoskin®
Vitiligo - Topical

Xylentra®
Wound care - Topical

IS - 107
Solid tumors - Injectable

IS - 217
Soriacare®
Psoriasis - Injectable
Topical

ISSAR'S Pre-Clinical
Pipeline

INDIA
INDIA
US FDA
INDIA
US FDA
IBD (Injectable)
Sepsis (Injectable)
Rheumatoid Arthritis
Atopic Dermatitis